Interesting threat against standard care in Lung cancer and Melanoma. Chemo companies have some real storm clouds on the horizon. They need to get on with how to improve OS results. The status quo is being challenged and they need to find better results or get kicked to the curb. Avastin and CA4P provide avenues for better results. Combination therapies are in play and the reasons for them are driven by big money.
Of course they knew. They know every time not just this time. They are like 100 percent lucky guessers or they know. i don't think the increase is good news but with the price so low we are talking less than $500,000 in investment money to put it down to 90 cents. That being the money flow behind 500,000 new shorts.
We are virtually worthless from an IP standpoint and net minus $6 million for the lousy management. The market has spoken and is flat out calling them a fraud. Fraud, meaning, liars, cheats, scoundrels, POS, dirt bags, con men, sleeze balls, did I miss any?
Again, what I think matters not, the market has spoken with its valuation of Oxigene.
Driscoll, Dai, Scweity, must be glowing with pride.
I had missed the Bank of Amerca numbers claiming 225,000 checks per day up from 150,000 a year ago. That's a 50 percent gain but we are only seeing half that.
Q4, in the past, has always been up a million or so over the trend line. Unfortunately, insider selling and the thug shorts have completely drained the life out of this company. The new IR firm is welcome news as the old one was awful.
But, then again, Debello is a challenge to make look good due to his stupidity. With, Thorton selling in tandem doesn't leave much room for the common holder.
If we get an $8 million dollar quarter not sure how high it will go if Debello and Thorton sell big lots at $4. But, if you look out, just as you said price is where it has been while profits and revenues are up significantly. We need a second big hit that secures growth out into the future.
When you think about gross margins on electronic checks and Bank of America handing Mitek a $15,000 payment 365 days a year...we sit here at $3. That's one top bank!
Banks still reporting 10 to 15 percent growth in mobile users with only 20 percent captured.
Guidance of 23.5 to 24.5 is disappointing giving ID checker and what the banks are reporting in mobile space. Will they blow away the top line? We have been waiting a long time for it. But, if so, Thorton bailing at $4 seems a mystery.
EK, I found where it appears he has sold out the October and November expiration since. 7/24 was the last of them. Unfortunately, he started selling July 16. Has 90,000 of those and it looks like they are on the sell block at $4.
Good news if there is any on this particular subject is their cost avg was $4.11 on options. That was without this years averaged in.
Not sure on Thortons agenda. Personally, I would not mind if both be gone and someone more accountable to shareholders takes over.
The downside is clearly check writing and whether it is in decline?
Not sure how to track this very well.
2) current burn is not the new burn.
4) shareholders turned down further dilution because management could not articulate the need. But, now we know the need was different than what we thought it might be back then. Shareholders sniffed this out.
5)FDA news, we got no real pop, someone knew. We should have got a 50 percent gain. But, they knew it was already #$%$ canned.
6)CFO was a CPA who you and I both know did not make these calls. The financing at $1.71 was done for the exact reason we are in now. They knew that when we knew the share price would crater. If not for the financing, we would be 50 to 60 cents right now.
7) The new CEO game created all the cover and ignorance to make it all seem believable. Come on Scweity was a BOD member for years. He had to approve the financing. He had to know more than he is plying dummy too
8) the shorts are not the problem here, management is the issue.
9) so yes, they figured out the SPA is no good, they knew that 8 months ago not a week ago.
1) Avastin/chemo approved
2) oxigene can not raise cash fast enough, $1.71 raise after Avastin news.
3) CEO replaced again
4) shareholders turn down further dilution.
5) FDA news very favorable but very little share appreciation.
6) CFO quits or is fired.
7) CEO to formerly review all aspects of the company.
8) Top three shareholders sell out in Q2.
9) Company announces there will be no SPA completely changes course.
I think between item #1 and item #2 they new #9 was the end game.
Steps 2 thru 8 were all the things that happened before they decided to tell us.
Personally, just my opinion, but there is potential criminal activity in the mix.
The SEC needs to put Barbara Riching in front of a grand jury. Sing Barbara sing.
Anyone thinks this is all coincidence is not being realistic.
Surprised with how weak this looks. A few things I like, Debello selling may have ended.
Need to get to late October when his options expire. Thorton selling is a much bigger question. None of his selling was anything expiring.
It doesn't seem like much has changed. Customers all in tact, growth rates appear normal, move to digital identity appears good. But, share price is rather weak.
The 52 week $1.80 low drops out next week. The bottom moving up can not hurt. Looking for more shares here and lower if possible.
Mano, nice post as usual, we end up in the same spot in the end for the same basic reasons.
Massive Incompetence. I hope the lights come on soon!
I am not following the legal use of "stakeholders" and what that implies.
Although, as it has been pointed out, it has become a favorite term.
Are they saying GOG and Christie trials are stakeholders? Baylor university?
That is a good post, it is also a problem with Oxgn. They have no friends left. They have torched too many people. Scweity has likely grown into this perspective. I see it like this...
Hey my old comrade in Biotech this is Scweity, what you think about us getting together and doing some collaborating and talk about our common ground? CLICK....as the phone goes silent...
Let's hope Schweity is a quick learner!!!
Looks like he is writing a new story on the issues this week. I believe his shots will be headed at the recent heads of this snake. Driscoll, Dai, Scweity. Call out the bums for what they are. Frankly, Biotech gets a bad name from leadership like this. Take them to the wood shed have no mercy. The share price might like the notion there is public scrutiny and a demand for accountability.
They have had their shots on goal, it's time to move the IP to someone who can score. We have seen enough. Good luck Daniel Ward.
Absolutely, nice shot on goal! We have certainly heard the resource staffing comments in the past. I made prediction that not one person ever enroll in either study headed by Oxigene. Your staffing comment is just one of my reasons for not buying the BS. Sell it Scweity sell it.
CPA, I think moving to a triple play strategy is an obvious potential for partnering, we are no longer a competitor but a potential partner. Although this sticks out very clearly, the company never implied anything towards this likely potential. All they had to do, is pump this point slightly and we might have had a neutral event. But, they obviously decided for retail to take it on the chin. It was designed that way. I don't think big money even flinched. They know the cash position and are likely all in tact.
It could be they were bluffing Chemo companies and we blinked. It could be a Chemo company blinked and said lets do a triple play. Of which, Schweity sets us down, they do some low ball share theft and then off to the end games. If we were bluffing and we blinked and there is no one interested....ought oh!!! Schweity got a big problem on his hands. That is officially the story and thus 90 cent share price. Is it the truth?
Frankly, I think they are selling it all and soon. The walls are closing in around them. Driscoll is getting eaten alive over at Flexion. Langdecker left being a slug. Scweity will not be the fall guy for this. He will make something happen. It may not be perfect but in his world the end justifies the means. This company has torched everyone it has ever associated with. Scweity knows there are few friends left if any. Getting a deal down cuts the head off this ugly snake. That's what I think he does and soon.
Root you don't remember conference call after conference call where Dai said FDA day, FDA day, FDA day, then it was Scweity and SPA and now POOF. Yeah that went on from early 2014 to Sep 30, 2015. According to Dai, from previous calls, we were working on things....all the way along during the ride. Seriously, what have 13 employees been doing for the past two years. $1 million a month.
Lot of red thumbs for anyone posting reality...
We were first and goal to goal and now we are 3rd and twenty.
Dai and Scweity pumped FDA day and the SPA....
not JPN and CPA. God forbid anyone hold them accountable for wasting 2 years and 25 MM dollars.
Wow a pile of red thumbs for anyone talking reality, lots of green thumbs for the all day pumpers. Scweity and the boys trying to make things look legit.
Obviously, I think retail is the target seller and giving the situation the buyers are the guys who will push it higher. Root has a point this could be a facilitated bottom but I think not the shorts but by Scweity. He is assisting a big money player to get in on the cheap. Who, great question.
Scweity was hooked up with a hedge fund in his last gig. I would expect he knows how to play some dirty pool. I don't think it just happened so. What happened, when it happened, how it happened, we're all premeditated to the nth degree.
I think Scweitybreally cares about his reputation. His personal branding is a big deal to him. I doubt this lasts Lang and by next conference call we have a much better price. If we don't, the next cc call will likely be a call to remember. In fact, going to this call with positive news is a must have. Very well could be Votrient news, a partnership, sale of 4503. I think we get a catalyst before the next call. Something...a win...for once.
I don't think they get on that call with nothing...